Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D)

Affiliations

• ¹ AC Camargo Cancer Center, Rua Pires da Mota, São Paulo, 1167, Brazil. noam.ponde@accamargo.org.br.
• ² Institut Jules Bordet, Brussels, Belgium. noam.ponde@accamargo.org.br.
• ³ Frontier Science Scotland (FSS), Kincraig, UK.
• ⁴ Institut Jules Bordet, Brussels, Belgium.
• ⁵ National Cancer Institute, Bethesda, MD, USA.
• ⁶ Breast International Group, Brussels, Belgium.
• ⁷ Sana Klinikum, Offenbach, Germany.
• ⁸ Novartis, Basel-City, Switzerland.
• ⁹ Dana-Farber Cancer Institute, Boston, USA.
• ¹⁰ Frontier Science and Technology Research Foundation, Boston, MA, USA.
• ¹¹ Mayo Clinic, Rochester, MN, USA.
• ¹² Mayo Clinic, Scottsdale, AZ, USA.
• ¹³ Mayo Clinic, Jacksonville, FL, USA.
• ¹⁴ Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium.